Tell the government you support the Lethbridge OPS

Please tell the Premier of Alberta and others why you support the Lethbridge Overdose Prevention Society (LOPS), by sending this letter. Replace the text in CAPITAL LETTERS with your information. Please share on social media and with others who support saving lives.

Why do we as families support LOPS and other harm reduction initiatives?

Kym Porter, MSTH advocate and local leader in Medicine Hat, AB, and other MSTh advocates were in Lethbridge for the opening night of the overdose prevention site. Learn what Kym and others experienced and why they were there.

A Friday Night to Remember

By Kym Porter.

MSTH volunteers at LOPS on opening night, setting up our banner. (Photo by: Victoria Nestorowicz)

MSTH volunteers at LOPS on opening night, setting up our banner. (Photo by: Victoria Nestorowicz)

On Friday, September 25, 2020, my husband, Kevin, and I got in the car and drove a few hours down the road from Medicine Hat to Lethbridge.  The purpose of this trip was like no other one we had ever taken.  We were heading to Galt Park, a beautiful, tree-lined green space in the middle of downtown to meet with two other members of MSTH, those being Lori Hatfield and Kari Urselescu.  The purpose of this meeting was to connect with a group of former staff members of Arches, the newly closed Supervised Consumption Site, the busiest site in North America, seeing over 600 client visits a day, a life-saving site now closed by an ideology based government in Alberta.  We were there to support Tim Slaney and others in setting up the first unsanctioned overdose prevention site in this city, the LOPS.  Lethbridge is a city extremely hard hit by the overdose crisis and the park has been referred to as the new epicenter for PWUD to gather.  The park has now become ‘an unsupervised consumption site.’

As the sun was setting, we met, introduced ourselves, and started to unload the tent and other paraphernalia required to ensure people remain safe and alive while they consume their drugs.  We also brought snacks, juice, and water to hand out. 

Kym Porter talking to media on the opening night of the OPS. (Photo by Victoria Nestorowicz)

Kym Porter talking to media on the opening night of the OPS. (Photo by Victoria Nestorowicz)

The tent was up in no time as was the MSTH banner.  Those of you familiar with the area will know the wind plays a very strong role in deciding how long tents etc remain standing and in this case, it was not long.  The banner, thought to be firmly planted in the ground, blew over just as I was to be interviewed by media.  It was then we decided to relocate the tent.  The banner, however, did not survive and went back into the trunk.

Because we kept the event on the ‘down-low’ we were unsure what to expect.  Tim had contacted a few trusted media outlets (Global TV Lethbridge and CBC) and they filmed the set up as well as the takedown three hours later.  They also interviewed a number of us as to what was the purpose of the OPS and why we felt it was necessary.

MSTH volunteers Lori Hatfield, Lori Vrebosh and Kari Urselescu. Lori came on the second anniversary of her son’s death to hand out harm reduction supplies and snacks together with her family. (Photo supplied by Lori Vrebosh.

MSTH volunteers Lori Hatfield, Lori Vrebosh and Kari Urselescu. Lori came on the second anniversary of her son’s death to hand out harm reduction supplies and snacks together with her family. (Photo supplied by Lori Vrebosh.

The snacks were an immediate hit and were a great way to make an initial connection with people in the park.  We helped fill bellies while making potential clients aware of what we were there for.  After about two hours from our set up, the first client used the tent to safely consume their drugs under the trained, watchful, caring and nonjudgmental eyes of the volunteer staff.  By the end of the evening, 4 people avoided overdose and possible death due to these concerned citizens taking the situation that the government had turned it’s back on, into their own capable, compassionate hands.

Just after eleven pm., we took down the tent and packed it and the supplies away to be set up again the following evening.  The snacks had all disappeared about a half-hour beforehand.  We packed up our vehicles, turned the heat on, and headed to our homes, knowing some of the people we met tonight would be sleeping in the park.

As we drove home and over the course of the past few days, I have reflected on the many different emotions that came during and after this experience.  The predominate feeling to come to me is/was humbleness.  I am in awe of the courage of these former staff to take up this challenge.  I am also filled with gratitude for them, for my fellow MSTH members that sat in the cold and greeted each person with hearts of kindness, for my husband who helped with set up, take down and driving home at one am, for the media present who covered the story objectively, for the people who donated funds to help get this off the ground, for the people who, once learning of this, have stepped up to help and for the people in the park who had no reason to trust us but did.

Setting all of this up involved many people including MSTH co-founder Lorna Thomas and Canadian Drug Policy Alliance worker Shay Vanderschaeghe.   MSTH members Kat Wahama and Traci Letts and long-time drug policy activist Ann Livingston were consultants to the process along with co-founder Petra Schulz who provided support from afar, given she is away in Germany.

The Lethbridge Overdose Prevention Society Tent is a beacon of hope. (Photo by Victoria Nestorowicz)

The Lethbridge Overdose Prevention Society Tent is a beacon of hope. (Photo by Victoria Nestorowicz)

I am sad about the stories and obvious trauma experienced by so many who stopped by.  Of course, I am sad for the lives lost so needlessly…but mainly, I am mad, no not mad, outraged!  I am outraged at a government ignoring evident based facts.  I am outraged at a government making decisions based on ideology and getting votes.  I am outraged at their coldheartedness.  I am confused and frustrated.  I know I am not alone by the support, sometimes silent, sometimes organizational in helping pull this off. 

This is not a one time only event.  The goal is to continue offering an OPS until it is not needed.  I would hope that day would be today however it is far off in the distance.  We will keep showing up because it is the kind, right thing to do.

Snacks are harm reduction. Kym Porter, Kari Urselescu, and Lori Hatfield on opening night (left to right). (Photo by Victoria Nestorowicz)

Snacks are harm reduction. Kym Porter, Kari Urselescu, and Lori Hatfield on opening night (left to right). (Photo by Victoria Nestorowicz)

Hundreds of Albertans Call on Jason Kenny to Save Canceled Treatment Program

Call to Maintain Funding for Alberta’s Injectable Opioid Agonist Treatment Clinics

The injection room of the iOAT program in Edmonton.  This highly effective program is slated to close in March 2020.

The injection room of the iOAT program in Edmonton. This highly effective program is slated to close in March 2020.

An open letter to the Government of Alberta Honourable Jason Kenney, Premier

2020-09-09 15_30_31-.png

Cc: Honourable Tyler Shandro, Minister of Health, Alberta Honourable Jason Luan, Associate Minister for Mental Health and Addictions David Shepherd, MLA, Opposition Critic for Health Heather Sweet, MLA, Opposition Critic for Mental Health and Addictions Dr. Deena Hinshaw, Chief Medical Officer of Health Honourable Patty Hajdu, Minister of Health, Canada

Dear Premier Kenney,

We, the undersigned are a group of Albertan patients, families, physicians, nurses, pharmacists, social workers, counsellors, peer workers, academics, and concerned citizens of the province. We are writing to express our grave concerns with your government’s decision to discontinue funding for Edmonton and Calgary’s injectable opioid agonist treatment (iOAT) programs after March 2021. Many of us have experience providing iOAT. Some of us and our families have directly benefited from receiving this life-saving treatment. All of us understand the need for iOAT as part of the full spectrum of care for people as they recover from the impacts of opioid use disorders and have been encouraged by the remarkable health and social benefits of this treatment to the people who receive it, to their families, and to the community at large.

While much of the health care system’s attention has turned towards protecting Albertans through the global COVID-19 pandemic, we also recognize that people at risk of severe adverse outcomes from substance use disorders are at the intersection of both the pandemic and the opioid overdose crisis which continues to exact its toll on communities across Canada. Alberta remains one of the hardest hit provinces with close to two people dying daily as a result of accidental opioid poisoning (1) and reports of increasing EMS calls for overdose (2) and the re-emergence of carfentanil in the drug supply3 make us concerned that this crisis has worsened over recent months. At this time more than any before, we must offer all evidence-based treatments to patients. The decision to discontinue funding to iOAT makes this option inaccessible for Albertans who may seek help as the programs are no longer able to accept new patients. Those who are currently benefiting from this treatment will be forced off of it in the coming months and many of these individuals may suffer severe adverse outcomes as a result.

In September 2019, the Canadian Research Initiative in Substance Misuse (CRISM) published National Guidelines on iOAT for Opioid Use Disorder. National experts thoroughly reviewed scientific evidence to develop these guidelines which were subject to expert peer review. The guidelines are clear: iOAT is a necessary treatment option for individuals with severe injection opioid use disorders that have not responded to other treatments (4). Benefits demonstrated through scientific study include reduced illicit opioid use, improved retention in treatment and health care, reduced criminal involvement and incarceration, reduced mortality, and improved overall health and social functioning (5-8). Furthermore, studies in both Europe and Canada have consistently proven that iOAT is cost effective given the significant reductions in criminal activity (9-11) and hospitalizations (12) with their associated costs.

The National Guideline on iOAT for Opioid Use Disorder is also clear that iOAT should not be discontinued while a patient continues to benefit from treatment. Decisions to transition to other treatment options should only be made in collaboration with the patient and based on thorough risk-benefit assessments. Discontinuing funding for the programs removes that opportunity and forces their health care providers to practice against national expert guidance. Patients who have developed trusting relationships with these programs will be disengaged once again and many may not avail themselves of other treatments that have failed them before. These prospects are tragic as patients will be at tremendous risk of destabilization and related harms, including overdose mortality.

The iOAT programs in Edmonton and Calgary are benchmarks of what an intensive, multidisciplinary, and comprehensive addiction treatment program can offer for individuals at critical periods in the trajectory of their recovery. Their patients have access to not only life-saving medication treatment from physicians and nurse practitioners but are also supported in their recovery by peer workers, mental health resources, social workers, nurses, pharmacists, and primary care. Albertans can be proud of what these clinics have accomplished and the positive impacts on their communities. With ongoing support and funding, they could no doubt continue to thrive, support recovery, and offer hope to highly vulnerable patients. Premier, please do not end this evidence-based, cost effective treatment in Alberta. We call on the Government of Alberta to reverse its decision to discontinue funding to the Edmonton and Calgary Injectable Opioid Agonist Treatment Clinics and to continue to support this critical treatment option for Albertans.

Sincerely,

2020-09-09 15_04_12-Window.png
2020-09-09 15_04_34-.png
2020-09-09 15_05_07-Window.png
2020-09-09 15_05_26-Window.png
2020-09-09 15_05_44-.png
2020-09-09 15_06_07-Window.png
2020-09-09 15_06_29-Window.png
2020-09-09 15_06_42-Window.png
2020-09-09 15_21_39-Window.png
2020-09-09 15_21_54-Window.png
2020-09-09 15_22_13-.png
2020-09-09 15_22_32-Window.png
2020-09-09 15_22_52-Window.png
2020-09-09 15_23_26-Window.png
2020-09-09 15_23_37-Window.png

References:

1. Health, Government of Alberta, June 2020, Alberta Opioid Response Surveillance Report: Q1 2020. https://www.alberta.ca/opioid-reports.aspx

2. https://www.cbc.ca/news/canada/edmonton/drug-users-warned-of-dangers-after-spike-in-opioid-related-ems-calls-in-edmonton-1.5600260

3. https://edmontonjournal.com/news/local-news/spike-in-carfentanil-deaths-opioid-overdoses-in-edmonton-prompts-health-warning

4. Canadian Research Initiative in Substance Misuse (CRISM). National Injectable Opioid Agonist Treatment for Opioid Use Disorder Clinical Guideline. Published September 23, 2019. https://crism.ca/projects/ioat-guideline/

5. Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database of Systematic Reviews. 2011(12). 10.1002/14651858.CD003410.pub4

6. Strang J, Groshkova T, Uchtenhagen A, et al. Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. The British Journal of Psychiatry. 2015;207(1):5-14. 10.1192/bjp.bp.114.149195

7. Oviedo-Joekes E, Guh D, Brissette S, et al. Hydromorphone compared with diacetylmorphine for long-term opioid dependence: A randomized clinical trial. JAMA Psychiatry. 2016;73(5):447-455. 10.1001/ jamapsychiatry.2016.0109

8. Oviedo-Joekes E, Brissette S, Marsh DC, et al. Diacetylmorphine versus Methadone for the Treatment of Opioid Addiction. New England Journal of Medicine. 2009;361(8):777-786. doi:10.1056/NEJMoa0810635

9. Nosyk B, Guh DP, Bansback NJ, et al. Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2012;184(6):E317-328. 10.1503/cmaj.110669

10. Byford S, Barrett B, Metrebian N, et al. Cost-effectiveness of injectable opioid treatment v. oral methadone for chronic heroin addiction. The British journal of psychiatry : the journal of mental science. 2013;203(5):341-349. 10.1192/bjp.bp.112.111583

11. Byford S, Barrett B, Metrebian N, et al. Cost-effectiveness of injectable opioid treatment v. oral methadone for chronic heroin addiction. The British journal of psychiatry : the journal of mental science. 2013;203(5):341-349. 10.1192/bjp.bp.112.111583

12. Bansback N, Guh D, Oviedo-Joekes E, et al. Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial. Addiction. 2018;113(7):1264-1273. 10.1111/ add.14171